Sign in
BDTX Stock Price, Chart, Stats & News
Black Diamond Therapeutics, Inc.
Save
Black Diamond Therapeutics, Inc. (BDTX) does not currently pay a dividend.
107.15M
Market cap
–
Current P/E
8.33x
Forward P/E
BDTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.78% |
Operating margin | 28.39% |
Pretax margin | 31.95% |
Net margin | 31.95% |
Effective tax rate | – |
ROA | 15.64% |
ROE | 17.46% |
D/E | 0.13x |
Interest coverage ratio | – |
BDTX valuation
P/E | – |
P/S | 1.66x |
P/B | 1.03x |
P/CF | 3.91x |
P/FCF | 3.93x |
P/OCF | 3.91x |
PEG | 0.98x |
EV multiple | 4.79x |
About
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations.
Similar securities
Based on sector and market capitalization
Report issue